Legal Representation
Attorney
Cynthia J. Walden
USPTO Deadlines 2 active 2 overdue
| Deadline Type | Event Code | Deadline Date | Days Until | Priority | Extension Available |
|---|---|---|---|---|---|
|
EXAMINER AMENDMENT
Examiner's Amendment Completed |
CNEA | Jan 06, 2023 | 913 days overdue | Low | No |
|
OPPOSITION
Notice of Publication |
NPUB | Feb 23, 2023 | 865 days overdue | Medium | Until Mar 23, 2023 |
Application History
20 events| Date | Code | Type | Description |
|---|---|---|---|
| Apr 11, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Apr 11, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jan 24, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jan 24, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jan 4, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Dec 22, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Dec 22, 2022 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Dec 22, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Dec 22, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Dec 22, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jun 23, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jun 23, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jun 23, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jun 21, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Oct 28, 2021 | ALIE | A | ASSIGNED TO LIE |
| Oct 28, 2021 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Oct 23, 2021 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Oct 22, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Oct 5, 2021 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Sep 21, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 042
Development of platform technology, namely, immunotherapy pharmaceutical platforms for use in manufacturing therapeutics related to inflammaging, inflammatory diseases, age-related diseases and cancer; Medical and scientific research and development services in the field of protein therapeutics and immunotherapeutics; pharmaceutical product development; pharmaceutical research and development services; Research and development of pharmaceuticals for the treatment of age-related and inflammatory diseases and cancer
First Use Anywhere:
May 28, 2018
First Use in Commerce:
May 28, 2018
Additional Information
Design Mark
The mark consists of A figure "8" followed by the letters "H" with an arrow, the letter "C" and the letter "W" with slanted lines separating the two outer strokes from the middle of the letter, with the word "Biologics" underneath the letters "C" and "W".
Pseudo Mark
EIGHT HCW BIOLOGICS
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"BIOLOGICS"